Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB‐4 index

The liver function of patients with hepatitis C virus (HCV) infection who obtained sustained virologic response (SVR) has been known to improve after HCV eradication. However, a predictor of liver function after SVR has not been definitively identified. The aim of this retrospective study was to identify a predictor of deteriorated liver function and Fibrosis‐4 (FIB‐4) index after SVR was achieved by direct‐acting antiviral (DAA) treatment.

[1]  T. Hamada,et al.  Relationship between various hepatic function scores and the formation of esophageal varices in patients with HIV/hepatitis C virus co‐infection due to contaminated blood products for hemophilia , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  J. Troya,et al.  Persistently altered liver test results in hepatitis C patients after sustained virological response with direct‐acting antivirals , 2018, Journal of viral hepatitis.

[3]  Yoshiyuki Suzuki,et al.  Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b , 2018, Journal of medical virology.

[4]  E. Herrmann,et al.  Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response , 2017, PloS one.

[5]  Rafael Stern,et al.  Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. , 2016, Journal of hepatology.

[6]  M. Manns,et al.  Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis , 2016, Journal of gastroenterology and hepatology.

[7]  J. Hoofnagle,et al.  Long‐term outcome of chronic hepatitis C after sustained virological response to interferon‐based therapy , 2013, Alimentary pharmacology & therapeutics.

[8]  M. Imamura,et al.  Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis , 2013, Journal of Gastroenterology.

[9]  J. Hoofnagle,et al.  Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. , 2012, Journal of hepatology.

[10]  V. Paradis,et al.  A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis , 2012, Hepatology.

[11]  B. Bacon,et al.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients , 2009, Hepatology.

[12]  Yoshiyuki Suzuki,et al.  Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C , 2009, Hepatology.

[13]  C. Ripoll,et al.  Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2006, The American Journal of Gastroenterology.

[14]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[15]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.